The DEA’s broader administrative proceeding to move all marijuana from Schedule I to Schedule III remains active but faces a procedural pause after the chief administrative law judge stayed hearings on September 29, 2026, to consider a new Government Accountability Office report on federal scheduling processes and allow supplemental briefing. Government and interested-party responses are due October 13, after which the judge will decide next steps before issuing a recommended decision. A separate April 2026 final rule already placed FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, with that action facing ongoing court challenges but remaining in effect. The current timeline for a final broader rule points toward early 2027 or later, subject to the ALJ’s ruling, DEA administrator review, and any further litigation or congressional action.